Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation

Abstract

Therapeutic messenger RNA vaccines enable delivery of whole antigens, which can be advantageous over peptide vaccines. However, optimal efficacy requires both intracellular delivery, to allow antigen translation, and appropriate immune activation. Here, we developed a combinatorial library of ionizable lipid-like materials to identify mRNA delivery vehicles that facilitate mRNA delivery in vivo and provide potent and specific immune activation. Using a three-dimensional multi-component reaction system, we synthesized and evaluated the vaccine potential of over 1,000 lipid formulations. The top candidate formulations induced a robust immune response, and were able to inhibit tumor growth and prolong survival in melanoma and human papillomavirus E7 in vivo tumor models. The top-performing lipids share a common structure: an unsaturated lipid tail, a dihydroimidazole linker and cyclic amine head groups. These formulations induce antigen-presenting cell maturation via the intracellular stimulator of interferon genes (STING) pathway, rather than through Toll-like receptors, and result in limited systemic cytokine expression and enhanced anti-tumor efficacy.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Isocyanide-mediated 3-CR for high-throughput synthesis of lipidoids.
Fig. 2: In vivo and in vitro screening of lipidoids for Fluc mRNA (mLuc) delivery.
Fig. 3: Top-performing lipidoids exhibit different anti-tumor immunity.
Fig. 4: Heterocyclic amine-containing lipidoids act as mRNA vaccines with robust antigen-specific T-cell and humoral responses.
Fig. 5: Cyclic lipidoids facilitate the maturation of APCs in local lymph nodes through STING-dependent activation of type I IFN.
Fig. 6: The effect of A18 mRNA antigen vaccines on tumor growth.

Data availability

The data supporting the findings of this study are available form the corresponding author upon reasonable request.

References

  1. 1.

    Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).

    CAS  Article  Google Scholar 

  2. 2.

    Pollard, C. et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol. Ther. 21, 251–259 (2013).

    CAS  Article  Google Scholar 

  3. 3.

    Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. Engl. 51, 8529–8533 (2012).

    CAS  Article  Google Scholar 

  4. 4.

    Kauffman, K. J., Webber, M. J. & Anderson, D. G. Materials for non-viral intracellular delivery of messenger RNA therapeutics. J. Control. Release 240, 227–234 (2016).

    CAS  Article  Google Scholar 

  5. 5.

    Richner, J. M. et al. Modified mRNA vaccines protect against Zika virus infection. Cell 168, 1114–1125.e10 (2017).

    CAS  Article  Google Scholar 

  6. 6.

    Kariko, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833–1840 (2008).

    CAS  Article  Google Scholar 

  7. 7.

    Li, K., Qu, S., Chen, X., Wu, Q. & Shi, M. Promising targets for cancer immunotherapy: TLRs, RLRs, and STING-mediated innate immune pathways. Int. J. Mol. Sci. 18, pii: E404 (2017).

    Article  Google Scholar 

  8. 8.

    Zevini, A., Olagnier, D. & Hiscottt, J. Crosstalk between cytoplasmic RIG-I and STING sensing pathways. Trends Immunol. 38, 194–205 (2017).

    CAS  Article  Google Scholar 

  9. 9.

    Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760–770 (2015).

    CAS  Article  Google Scholar 

  10. 10.

    Corrales, L. et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11, 1018–1030 (2015).

    CAS  Article  Google Scholar 

  11. 11.

    Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396–401 (2016).

    Article  Google Scholar 

  12. 12.

    Fotin-Mleczek, M. et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J. Gene Med. 14, 428–439 (2012).

    CAS  Article  Google Scholar 

  13. 13.

    Schlee, M. et al. Recognition of 5’ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 31, 25–34 (2009).

    CAS  Article  Google Scholar 

  14. 14.

    Barbalat, R., Ewald, S. E., Mouchess, M. L. & Barton, G. M. Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 29, 185–214 (2011).

    CAS  Article  Google Scholar 

  15. 15.

    Uchida, S. et al. Designing immunostimulatory double stranded messenger RNA with maintained translational activity through hybridization with poly a sequences for effective vaccination. Biomaterials 150, 162–170 (2018).

    CAS  Article  Google Scholar 

  16. 16.

    Van Lint, S. et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res. 72, 1661–1671 (2012).

    Article  Google Scholar 

  17. 17.

    Broos, K. et al. Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon. Mol. Ther. Nucleic Acids 5, e326 (2016).

    CAS  Article  Google Scholar 

  18. 18.

    Iurescia, S., Fioretti, D. & Rinaldi, M. Nucleic acid sensing machinery: targeting innate immune system for cancer therapy. Recent Pat. Anticancer Drug Discov. 13, 2–17 (2018).

    CAS  Article  Google Scholar 

  19. 19.

    Wang, J., Li, P. & Wu, M. X. Natural STING agonist as an “ideal” adjuvant for cutaneous vaccination. J. Invest. Dermatol. 136, 2183–2191 (2016).

    CAS  Article  Google Scholar 

  20. 20.

    Luo, M. et al. A STING-activating nanovaccine for cancer immunotherapy. Nat. Nanotechnol. 12, 648–654 (2017).

    CAS  Article  Google Scholar 

  21. 21.

    Caucheteux, S. M. & Piguet, V. New cutaneous vaccine adjuvant that STINGs a little less. J. Invest. Dermatol. 136, 2127–2128 (2016).

    CAS  Article  Google Scholar 

  22. 22.

    Iribarren, K. et al. Trial watch: immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology 5, e1088631 (2016).

    Article  Google Scholar 

  23. 23.

    Holm, C. K. et al. Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat. Immunol. 13, 737–743 (2012).

    CAS  Article  Google Scholar 

  24. 24.

    Fu, J. et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl. Med. 7, 283ra252 (2015).

    Google Scholar 

  25. 25.

    Wilson, D. R. et al. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. Nanomedicine 14, 237–246 (2018).

    CAS  Article  Google Scholar 

  26. 26.

    Demaria, O. et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc. Natl Acad. Sci. USA 112, 15408–15413 (2015).

    CAS  Article  Google Scholar 

  27. 27.

    Hulme, C. & Gore, V. “Multi-component reactions: emerging chemistry in drug discovery” ‘from xylocain to crixivan’. Curr. Med. Chem. 10, 51–80 (2003).

    CAS  Article  Google Scholar 

  28. 28.

    Sahay, G. et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat. Biotechnol. 31, 653–658 (2013).

    CAS  Article  Google Scholar 

  29. 29.

    Gilleron, J. et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31, 638–646 (2013).

    CAS  Article  Google Scholar 

  30. 30.

    Cheng, N. et al. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. JCI Insight 3, pii: 120638 (2018).

    Article  Google Scholar 

  31. 31.

    Tanaka, Y., Hasui, T. & Suginome, M. Acid-free, aminoborane-mediated Ugi-type reaction leading to general utilization of secondary amines. Org. Lett. 9, 4407–4410 (2007).

    CAS  Article  Google Scholar 

  32. 32.

    Kazmaier, U. & Ackermann, S. A straightforward approach towards thiazoles and endothiopeptides via Ugi reaction. Org. Biomol. Chem. 3, 3184–3187 (2005).

    CAS  Article  Google Scholar 

  33. 33.

    Pan, S. C. & List, B. Catalytic three-component Ugi reaction. Angew. Chem. Int. Ed. Engl. 47, 3622–3625 (2008).

    CAS  Article  Google Scholar 

  34. 34.

    Fenton, O. S. et al. Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery. Adv. Mater. 28, 2939–2943 (2016).

    CAS  Article  Google Scholar 

  35. 35.

    Akinc, A. et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26, 561–569 (2008).

    CAS  Article  Google Scholar 

  36. 36.

    Koopmanschap, G., Ruijter, E. & Orru, R. V. Isocyanide-based multicomponent reactions towards cyclic constrained peptidomimetics. Beilstein J. Org. Chem. 10, 544–598 (2014).

    Article  Google Scholar 

  37. 37.

    Whitehead, K. A. et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat. Commun. 5, 4277 (2014).

    CAS  Article  Google Scholar 

  38. 38.

    Semple, S. C. et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172–176 (2010).

    CAS  Article  Google Scholar 

  39. 39.

    Kauffman, K. J. et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 15, 7300–7306 (2015).

    CAS  Article  Google Scholar 

  40. 40.

    Whitehead, K. A. et al. In vitro-in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery. ACS Nano 6, 6922–6929 (2012).

    CAS  Article  Google Scholar 

  41. 41.

    Chahal, J. S. et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc. Natl Acad. Sci. USA 113, E4133–E4142 (2016).

    CAS  Article  Google Scholar 

  42. 42.

    Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226 (2017).

    CAS  Article  Google Scholar 

  43. 43.

    Gu, B., Linehan, B. & Tseng, Y. C. Optimization of the buchi B-90 spray drying process using central composite design for preparation of solid dispersions. Int. J. Pharm. 491, 208–217 (2015).

    CAS  Article  Google Scholar 

  44. 44.

    Heyes, J., Palmer, L., Bremner, K. & MacLachlan, I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release 107, 276–287 (2005).

    CAS  Article  Google Scholar 

  45. 45.

    Oberli, M. A. et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 17, 1326–1335 (2017).

    CAS  Article  Google Scholar 

  46. 46.

    Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. & Moon, J. J. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat. Mater. 16, 489–496 (2017).

    CAS  Article  Google Scholar 

  47. 47.

    Ma, D. Y. & Clark, E. A. The role of CD40 and CD154/CD40L in dendritic cells. Semin. Immunol. 21, 265–272 (2009).

    CAS  Article  Google Scholar 

  48. 48.

    Walseng, E. et al. Dendritic cell activation prevents MHC class II ubiquitination and promotes MHC class II survival regardless of the activation stimulus. J. Biol. Chem. 285, 41749–41754 (2010).

    CAS  Article  Google Scholar 

  49. 49.

    Deering, R. P., Kommareddy, S., Ulmer, J. B., Brito, L. A. & Geall, A. J. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin. Drug Deliv. 11, 885–899 (2014).

    CAS  Article  Google Scholar 

  50. 50.

    Bloom, M. B. et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185, 453–459 (1997).

    CAS  Article  Google Scholar 

  51. 51.

    Aviles, E. et al. Synthesis and preliminary biological evaluation of a small library of hybrid compounds based on Ugi isocyanide multicomponent reactions with a marine natural product scaffold. Bioorg. Med. Chem. Lett. 25, 5339–5343 (2015).

    CAS  Article  Google Scholar 

  52. 52.

    Ugi, I., Werner, B. & Dömling, A. The chemistry of isocyanides, their multicomponent reactions and their libraries. Molecules 8, 4 (2003).

    Article  Google Scholar 

  53. 53.

    Wada, J. et al. A new nonsteroidal antiinflammatory agent. 2-Substituted 5- or 6-benzothiazoleacetic acids and their derivatives. J. Med. Chem. 16, 930–934 (1973).

    CAS  Article  Google Scholar 

  54. 54.

    Ohkuri, T. et al. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site. Cancer Immunol. Immunother. 66, 705–716 (2017).

    CAS  Article  Google Scholar 

  55. 55.

    Rao, R. S., Kumar, C. G., Prakasham, R. S. & Hobbs, P. J. The Taguchi methodology as a statistical tool for biotechnological applications: a critical appraisal. Biotechnol. J. 3, 510–523 (2008).

    CAS  Article  Google Scholar 

  56. 56.

    Belliveau, N. M. et al. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol. Ther. Nucleic Acids 1, e37 (2012).

    Article  Google Scholar 

  57. 57.

    Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20212–20217 (2013).

    CAS  Article  Google Scholar 

  58. 58.

    Maruggi, G. et al. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine 35, 361–368 (2017).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This work was supported by Translate Bio (Lexington, MA) and the Juvenile Diabetes Research Foundation (grant nos. 17-2007-1063 and 3-PDF-2015-91-A-N). This work is supported in part by the Cancer Center Support (core) (grant no. P30-CA14051) from the National Institutes of Health. D.G.A. is a consultant for Translate Bio. L.M. was supported by a Misrock postdoctoral fellowship. D.D. was supported by an EPSRC E-TERM Fellowship (EP/I017801/1) and a Marie Sklodowska Curie Fellowship (IF/798348). K.S. was supported by the Ruth L. Kirschstein NRSA Postdoctoral Fellowship (no. 1F32EB025688-01A1) from the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health. L.L. and J.H. were supported by a Ming Wai Lau grant from the Ming Wai Lau Centre for Reparative Medicine, Karolinska Institutet. The authors would like to acknowledge the use of resources at the W. M. Keck Biological Imaging Facility (Whitehead Institute) and at the Microscopy, Histology, Animal Imaging & Preclinical Testing and Flow Cytometry Core Facilities (Swanson Biotechnology Center, David H. Koch Institute for Integrative Cancer Research at MIT), and acknowledge Wuxi Further Pharmaceutical Co., Ltd for synthesizing and providing lipid materials.

Author information

Affiliations

Authors

Contributions

L.M. and D.G.A. designed experiments and analyzed data. L.L. designed the chemical structures. L.M., Y.H., D.D., Y.S., J.C., K.S., W.G. and J.H. performed experiments. J.L. and L.M. drew the schematic figures. L.M., D.D., J.C.D., Y.H. and D.G.A. wrote the manuscript. R.L. and D.G.A. supervised the study. All authors discussed the results and assisted in the preparation of the manuscript.

Corresponding author

Correspondence to Daniel G. Anderson.

Ethics declarations

Competing interests

L.M., Y.H., L.L. and D.G.A. have filed a patent for the development of the described lipids synthesized using the three-component reaction. R.L. receives licensing fees (to patents in which he was an inventor on) from, invested in, consults (or was on scientific advisory boards or boards of directors) for, lectured (and received a fee), or conducts sponsored research at MIT for which he was not paid for the following entities: 7th Sense, Abpro, Aleph Farms, Alkermes, Allevi, Alnylam, Artificial Cells, Arsenal Medical, BASF, Celero, Cellomics, Cellular Biomedical, Clarus, Clontech, Combined Therapeutics, Conference Forum, Curis, Domain, Eagle, Echo, Edge, Evox, Fate Therapeutics, Frequency Therapeutics, Genscript, Glycobia, Glympse, Grandhope, Greenlight, HKF Technologies, Horizon Discovery, Humacyte, Indivor, Inovio, Institute of Immunology, In Vivo Therapeutics, Ironwood Pharmaceuticals, Kallyope, Kensa, Keratinx, KSQ Therapeutics, Laderatech, Inc., Landsdowne Labs, Like Minds, Luminopia, Luye, Lyndra, Lyra, Medical Kinetics, Merck, Micelle, Moderna, Momenta, Monsanto, Mylan, Nanobiosym, Nanobiotix, Noveome, Particles for Humanity, Perosphere, Pfizer, Polaris, Portal, Pulmatrix, Puretech, Roche, Rubius, Secant, Selecta Biosciences, Setsuro, Shiseido, Sigilon, Sio2, SQZ, Stembiosys, Suono Bio, T2 Biosystems, Tara, Taris Biomedical, Tarveda, Third Rock, Tiba, Tissium, Titan Pharma, Unilever, VasoRX, Verseau Therapeutics, Vivtex, Wiki Foods and Zenomic.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Supplementary Figs. 1–24, Tables 1, 2 and 4, and Notes 1–4.

Reporting Summary

Supplementary Table 3

Characterization of the top-performing lipids.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Miao, L., Li, L., Huang, Y. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol 37, 1174–1185 (2019). https://doi.org/10.1038/s41587-019-0247-3

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing